Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study
Por:
Requena, GA, Rodríguez-Veiga, R, Gil, C, Botella, C, Aguiar, E, Trigo, F, Colorado, M, del Castillo, TD, Barragan, E, Tormo, M, Arbolí, ER, López, JS, Boyero, RG, Castaño, T, Puente, PH, Riquelme, MAR, Lloris, MJS, Algarra-Algarra, L, Rodriguez-Medina, C, Melo, CLS, Gomez, JL, Vives, S, Salamero, O, Amigo, ML, Nuñez, MV, Rojas, C, Bass, F, García-Fortes, M, Vicente, BV, Polo, M, Benavente, C, Madrigal, MD, Espinoza, M, Pérez-Encinas, M, Barciela, MLA, Bautista, G, Solana-Altabella, A, Cano-Ferri, I, Colmenares, R, García-Ramírez, P, Alis, FI, García, MB, Rodríguez-Macías, G, López, M, Hernández, AYO, Cerveró, CJ, Martínez-Cuadrón, D, Chorao, P, Burgues, JMB and Montesinos, P
Publicada:
22 abr 2026
Ahead of Print:
1 abr 2026
Resumen:
In a large multicenter real-world cohort, we aimed to evaluate outcomes of FLAG-Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998-2024), including patients with primary refractory disease (36.9%) and first relapse episode (63.1%), with a median age of 52 years. Complete remission composite (CRc) was achieved 56.8%, including complete remission (CR) in 51.0%, CR with incomplete recovery in 4.0%, and morphological-free-state in 1.8%, enabling 35.2% of patients and 62% of responders to proceed to allogeneic transplantation without morphological disease. With median follow-up of 50.9 months, median overall survival (OS) was 10.2 months, with 5-year OS rate of 21.6%. Prior allogeneic transplantation (HR 0.54; p < 0.001) and relapse-free interval >= 1 year (HR 0.75; p = 0.024) independently predicted improved OS, whereas modified high-risk cytogenetics including t(8; 21) (HR 3.58; p < 0.001), FLT3-ITD mutation at primary diagnosis (HR 1.61; p < 0.001), and age >= 60 (HR 1.43; p < 0.001) conferred inferior OS. Validation of the SALFLAGE score demonstrated moderate discrimination (C-index 0.67), with 5-year survival of 38.4%, 27.2%, and 12.7% across risk categories (p < 0.001). Outcomes improved over periods (1998-2005 vs. 2006-2016 vs. 2017-2024): 30-day mortality was 6.9% vs. 9.3% vs. 5.0%, respectively (p = 0.030), and median OS was 7.8 versus 9.4 versus 11.1 months, respectively (p = 0.16). We confirm FLAG-Ida as a reference salvage regimen in fit R/R AML and validate the SALFLAGE score in this setting.
Filiaciones:
Requena, GA:
Montpellier Univ Hosp, Serv Hematol Clin, Montpellier, France
Univ Montpellier, Montpellier, France
Rodríguez-Veiga, R:
Hosp U La Fe, Serv Hematol, Valencia, Spain
Gil, C:
Hosp Gen Alicante, Serv Hematol, Alicante, Spain
Botella, C:
Hosp Gen Alicante, Serv Hematol, Alicante, Spain
Aguiar, E:
Ctr Hosp Sao Joao, Serv Hematol, Porto, Portugal
Trigo, F:
Ctr Hosp Sao Joao, Serv Hematol, Porto, Portugal
Colorado, M:
Hosp U Marques de Valdecilla, Serv Hematol, Santander, Spain
del Castillo, TD:
Hosp Cent Asturias, Serv Hematol, Oviedo, Spain
Barragan, E:
Hosp U La Fe, Serv Hematol, Valencia, Spain
Tormo, M:
Hosp Clin Univ Valencia, Serv Hematol, Valencia, Spain
Arbolí, ER:
Hosp U Virgen del Rocio, Serv Hematol, Seville, Spain
López, JS:
Hosp Reina Sofia, Serv Hematol, Cordoba, Spain
Boyero, RG:
Hosp Gen Castellon, Serv Hematol, Castellon de La Plana, Spain
Castaño, T:
Hosp Fdn Jimenez Diaz, Serv Hematol, Madrid, Spain
Puente, PH:
Hosp Ramon & Cajal, Serv Hematol, Madrid, Spain
Riquelme, MAR:
Hosp Guillermo Grant Benavente Concepcion, Serv Hematol, Concepcion, Chile
Lloris, MJS:
Hosp Dr Peset, Serv Hematol, Valencia, Spain
Algarra-Algarra, L:
Hosp Gen Albacete, Serv Hematol, Albacete, Spain
Rodriguez-Medina, C:
Hosp Dr Negrin, Serv Hematol, Las Palmas Gran Canaria, Spain
Melo, CLS:
Clin Foscal, Serv Hematol, Bucaramanga, Colombia
Gomez, JL:
Hosp Univ Burgos, Serv Hematol, Burgos, Spain
:
Hosp U Germans Trias i Pujol, Serv Hematol, Badalona, Spain
Salamero, O:
Hosp U Vall dHebron, Serv Hematol, Barcelona, Spain
Amigo, ML:
Hosp Morales Meseguer, Serv Hematol, Murcia, Spain
Nuñez, MV:
Hosp Arnau Vilanova, Serv Hematol, Valencia, Spain
Rojas, C:
Hosp Gustavo Fricke, Serv Hematol, Valparaiso, Chile
Bass, F:
Hosp Salvador, Serv Hematol, Providencia, Chile
García-Fortes, M:
Hosp U Virgen de la Victoria, Serv Hematol, Malaga, Spain
Vicente, BV:
Hosp U Salamanca, Serv Hematol, Salamanca, Spain
Polo, M:
Hosp Clin San Carlos, Serv Hematol, Madrid, Spain
Benavente, C:
Hosp Clin San Carlos, Serv Hematol, Madrid, Spain
Madrigal, MD:
Hosp U Virgen de la Macarena, Serv Hematol, Seville, Spain
Espinoza, M:
Clin Davila, Serv Hematol, Recoleta, Chile
Pérez-Encinas, M:
Serv Hematol Santiago de Compostela, Santiago De Compostela, Spain
Barciela, MLA:
Hosp Montecelo, Serv Hematol, Complejo Hosp, Pontevedra, Spain
Bautista, G:
Hosp Puerta de Hierro, Serv Hematol, Madrid, Spain
Solana-Altabella, A:
Hosp U La Fe, Serv Hematol, Valencia, Spain
Cano-Ferri, I:
Hosp U La Fe, Serv Hematol, Valencia, Spain
Colmenares, R:
Hosp 12 Octubre, Serv Hematol, Madrid, Spain
García-Ramírez, P:
Hosp Univ Principe Asturias, Alcala De Henares, Madrid, Spain
Alis, FI:
Hosp Gen Valencia, Valencia, Spain
García, MB:
Hosp Carlos Haya, Complejo Hosp Reg Malaga, Malaga, Spain
Rodríguez-Macías, G:
Hosp Gen Univ Gregorio Maranon, Madrid, Spain
López, M:
Clin Alemana Santiago, Santiago, Chile
Hernández, AYO:
Hosp Univ Nuestra Senora Candelaria, Santa Cruz de Tenerife, Spain
Cerveró, CJ:
Hosp Virgen de la Luz, Cuenca, Spain
Martínez-Cuadrón, D:
Hosp U La Fe, Serv Hematol, Valencia, Spain
Chorao, P:
Hosp U La Fe, Serv Hematol, Valencia, Spain
Burgues, JMB:
Hosp San Pedro de Alcantara, Serv Hematol, Caceres, Spain
Montesinos, P:
Hosp U La Fe, Serv Hematol, Valencia, Spain
hybrid
|